GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS BENIGN PROSTATIC HYPERPLASIA (BPH)-1

HPGST SSB: Cardura XL

TGST SSB: Cardura XL

Status: CVS Caremark® Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

POLICY

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of at least one generic alpha-1 adrenergic blocker drug, generic 5-alpha reductase inhibitor drug, or generic alpha-1 adrenergic blocker/5-alpha reductase inhibitor combination product within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

Authorization may be granted for the requested branded alpha-1 adrenergic blocker when ONE of the following criteria are met:

- The patient has experienced an inadequate treatment response after at least a 30 day trial of at least ONE generic alpha-1 adrenergic blocker drug, generic 5-alpha reductase inhibitor drug, or generic alpha-1 adrenergic blocker/5-alpha reductase inhibitor combination product
- The patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least ONE generic alpha-1 adrenergic blocker drug, generic 5-alpha reductase inhibitor drug, or generic alpha-1 adrenergic blocker/5-alpha reductase inhibitor combination product
- The patient has experienced an intolerance to at least ONE generic alpha-1 adrenergic blocker drug, generic 5-alpha reductase inhibitor drug, or generic alpha-1 adrenergic blocker/5-alpha reductase inhibitor combination product

DURATION OF APPROVAL (DOA)

605-D: DOA: 24 months606-D: DOA: 24 months

REFERENCES

N/A

GSTP BPH-Alpha-1 Adrenergic Blockers Policy 605-D, 606-D UDR 05-2024

© 2024 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.